The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
This study evaluated the efficacy and safety of the first-line chemotherapy regimens in advanced gastric carcinoma (AGC). METHODOGY: In this study, 116 patients who had advanced stage gastric adenocarcinoma were evaluated. The patients receiving Cisplatin/5-Flourouracil (CF) regimen (n=36) were compared with either those receiving Epirubicin/Cispatin/5-Flourouracil (ECF) regimen (n=40) or those receiving Docetaxel/Cispatin/5-Flourouracil (DCF) regimen (n=40). The overall response rate (ORR) was 18%, 30%, and 40% with CF, ECF, and DCF, respectively. Progression-free survival (PFS) was 4.3, 4.4 and 5.8 months for CF, ECF and DCF, respectively. Although overall survival was similar in all 3 groups, 1-year and 2-year survival rates were better on DCF group compared to the other two groups. The results of our study suggest that DCF is superior in terms of ORR and PFS in comparison to CF and ECF combinations in AGC.